Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria.

Thomas O'ConnellMarric BuessingScott JohnsonLufei TuSimu K ThomasIoannis Tomazos

Published in: PharmacoEconomics (2021)

In adults with paroxysmal nocturnal hemoglobinuria, ravulizumab is associated with improved health-related quality of life and provides a large cost saving from the perspective of a US payer, when compared with eculizumab.

Keyphrases

atrial fibrillation
blood pressure
obstructive sleep apnea
sleep apnea
sleep quality
catheter ablation
depressive symptoms